Sponsors (2)
This is not an official government website.
Copyright © 2026 PLEJ LC. All rights reserved.
Prohibits executive agencies from procuring or contracting for biotechnology equipment or services from companies placed on an OMB-maintained list of "biotechnology companies of concern," and bars obligating loan or grant funds for those items. Requires OMB to publish and update the list based on input from national security and agency officials, to issue implementing guidance, and requires the FAR to be revised to implement the procurement ban. Establishes phased effective dates tied to the FAR revision, a five-year limited exclusion for preexisting contracts, case-by-case waiver paths with OMB approval and congressional notice, and a separate waiver path for overseas health care services. Also mandates intelligence-community risk assessments and recurring reporting on foreign-held U.S. human multiomic data and related nefarious activities.
The bill strengthens national security and procurement oversight to limit foreign access to sensitive multiomic data, but does so at the cost of potentially disrupting research and clinical operations, increasing costs for researchers and taxpayers, and slowing urgent procurements.
Federal agencies, contractors, and taxpayers: the bill bars purchases of biotech equipment and services from companies identified as foreign security risks, reducing the chance that foreign actors gain access to U.S. human multiomic data.
Congress, federal agencies, and the public: requires DNI risk assessments and annual reporting on threats from foreign-held U.S. multiomic data, increasing visibility of biological intelligence risks for oversight and policy-making.
Federal procurement officials, agencies, and contractors: creates an OMB-led process and FAR revisions to list risky biotech suppliers and standardize procurement controls so agencies have clearer rules to avoid high-risk vendors.
Hospitals, clinical labs, researchers, and patients with chronic conditions: agencies and contractors may lose access to specialized sequencers, software, or services, disrupting research, diagnostics, and clinical programs that rely on that technology.
Universities, small research labs, and taxpayers: restrictions on using federal grant/loan funds and the need to replace disallowed vendors/equipment could force researchers to absorb replacement costs, lose eligibility for funding, and increase overall program costs for taxpayers.
Federal agencies and the public: waivers are limited and require OMB approval plus congressional notice, which could delay urgent procurements and complicate emergency public-health responses or other time‑sensitive operations.
Introduced December 11, 2025 by Gary C. Peters · Last progress December 11, 2025